SONN

Sonnet BioTherapeutics Holdings (SONN)

About Sonnet BioTherapeutics Holdings (SONN)

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Details

Daily high
$1.42
Daily low
$1.34
Price at open
$1.36
52 Week High
$17.84
52 Week Low
$1.30
Market cap
4.2M
Dividend yield
0.00%
Volume
66,902
Avg. volume
43,912
P/E ratio
-.12

Sonnet BioTherapeutics Holdings News

Details

Daily high
$1.42
Daily low
$1.34
Price at open
$1.36
52 Week High
$17.84
52 Week Low
$1.30
Market cap
4.2M
Dividend yield
0.00%
Volume
66,902
Avg. volume
43,912
P/E ratio
-.12